Beam Therapeutics (NASDAQ:BEAM) Stock Rating Lowered by Wall Street Zen

by · The Cerbat Gem

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Other research analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating on shares of Beam Therapeutics in a research report on Tuesday, October 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beam Therapeutics in a report on Thursday, October 15th. William Blair upgraded shares of Beam Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Bank of America restated a “buy” rating and set a $47.00 price objective on shares of Beam Therapeutics in a research report on Wednesday, July 8th. Finally, Canaccord Genuity Group upped their target price on Beam Therapeutics from $78.00 to $79.00 and gave the company a “buy” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $46.90.

Read Our Latest Stock Analysis on BEAM

Beam Therapeutics Price Performance

BEAM stock opened at $27.23 on Friday. Beam Therapeutics has a fifty-two week low of $20.23 and a fifty-two week high of $38.26. The stock has a market capitalization of $2.81 billion, a price-to-earnings ratio of -31.66 and a beta of 2.23. The company has a debt-to-equity ratio of 0.09, a current ratio of 14.57 and a quick ratio of 14.57. The business’s fifty day moving average price is $25.93 and its two-hundred day moving average price is $28.19.

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.07). The firm had revenue of $0.49 million during the quarter, compared to the consensus estimate of $16.37 million. Beam Therapeutics had a negative net margin of 54.75% and a negative return on equity of 30.71%. The company’s revenue was down 94.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.00) earnings per share. On average, equities analysts anticipate that Beam Therapeutics will post -4.49 earnings per share for the current year.

Insider Activity at Beam Therapeutics

In related news, CEO John Evans sold 25,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.57, for a total transaction of $589,250.00. Following the completion of the transaction, the chief executive officer owned 1,047,205 shares in the company, valued at $24,682,621.85. This represents a 2.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Beam Therapeutics during the second quarter worth $308,796,000. ARCH Venture Management LLC acquired a new position in shares of Beam Therapeutics during the 2nd quarter worth $155,771,929. ADAR1 Capital Management LLC purchased a new position in Beam Therapeutics in the first quarter valued at about $34,467,000. Bank of America Corp DE acquired a new position in shares of Beam Therapeutics during the 2nd quarter valued at $24,733,000. Finally, Elmind Capital LP bought a new position in Beam Therapeutics in the 2nd quarter worth $16,347,920. 99.68% of the stock is owned by institutional investors and hedge funds.

More Beam Therapeutics News

Here are the key news stories impacting Beam Therapeutics this week:

  • Positive Sentiment: Clinical optimism remains a potential support. Beam reviewed initial Phase 1/2 data for BEAM-301 in glycogen storage disease type 1a, keeping investor attention on the company’s base-editing pipeline and future milestone potential. Beam Therapeutics reviews initial BEAM-301 data
  • Positive Sentiment: Citi initiated or reiterated a Buy view on Beam, while broader healthcare commentary also identified BEAM among attractive stocks. This reinforces the bullish long-term case centered on gene editing and potential pipeline catalysts. Beam Therapeutics gets a Buy from Citi
  • Positive Sentiment: Shares previously gained 15.6% on above-average volume, suggesting strong short-term interest. However, the accompanying analysis cautioned that recent earnings-estimate trends may not sustain the rally. Beam Therapeutics moves 15.6% higher
  • Neutral Sentiment: Beam crossed above its 200-day moving average, a potentially constructive technical signal, but the report tied the move to an analyst downgrade, limiting its significance. Beam crosses above its 200-day moving average
  • Negative Sentiment: Wedbush cut its price target, adding pressure to the stock after its recent advance. The downgrade signals more cautious near-term expectations even as other analysts remain constructive. Wedbush cuts Beam Therapeutics price target
  • Negative Sentiment: HC Wainwright retained a Buy rating but lowered most 2026–2029 EPS forecasts, including FY2026 to a loss of $4.67 per share and FY2027 to a loss of $5.23. The revisions highlight continued heavy losses and delayed profitability; FY2030 was modestly improved to a $1.48 loss. HC Wainwright earnings estimate revisions

Beam Therapeutics Company Profile

(Get Free Report)

Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines for patients with serious diseases. The company’s platform uses base editing, a form of gene editing designed to make targeted changes to individual DNA letters without creating double-strand breaks. Beam is also advancing related editing technologies and delivery systems intended to improve the precision and effectiveness of genetic treatments.

Beam’s pipeline includes investigational programs for diseases such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type Ia.

Further Reading